Ph+ Acute Lymphoblastic Leukemia research hub

Ponatinib for the management of minimal residual disease (MRD) and hematologic relapsein adult Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients.ALL2620

This study looks at a medicine called ponatinib for adults with a type of leukaemia (Ph+ ALL) that has come back or hasn't fully gone away. We want to see how well it reduces remaining leukaemia cells after 3 months, sometimes with other chemotherapy drugs.